Navigation Links
Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009
Date:1/28/2010

GAAP other income and expenses excluding expenses related to the accounting for convertible debt instruments that may be settled in cash upon conversion, including partial settlements, in accordance with ASC 470-20, Debt, and unrealized gains or losses on the equity conversion option included in the HeartWare loan agreement.

Non-GAAP tax rate consists of the GAAP tax rate adjusted for the tax effect of the adjustments from GAAP net income to non-GAAP net income.

Management believes that it is useful in measuring Thoratec's operations to exclude amortization of intangibles.  These costs are primarily fixed at the time of an acquisition and, unlike other fixed costs that result from ordinary operations, are the result of infrequent and irregular events.

Because of varying valuation methodologies, subjective assumptions and the variety of award types that companies can use, Thoratec management believes that providing non-GAAP financial measures that exclude share-based compensation allows investors to compare Thoratec's recurring core business operating results to those of other companies and over multiple periods.  The exclusion also enhances investors' ability to review Thoratec's business from the same perspective as Thoratec management, which believes that share-based compensation expense is not directly attributable to the underlying performance of the company's business operations.

Due to the subjective assumptions used to develop non-cash interest expense related to the accounting for convertible debt instruments that may be settled in cash upon conversion, including partial settlements, in accordance with ASC 470-20, Debt, Thoratec management believes that providing non-GAAP financial measures that exclude such expense allows investors to compare Thoratec's recurring core business operating results to those of other companies and over multiple periods.  The exclusion also
'/>"/>

SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
4. Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology
5. Thoratec Schedules Fiscal 2009 Year-End Conference Call, Webcast
6. Thoratec Presentation at Canaccord Adams Conference to be Webcast
7. Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy
8. Thoratec Investor Meeting to Review HeartMate II (R) Destination Therapy Trial Data to Be Webcast
9. Thoratec Presentation at Piper Jaffray Conference to be Webcast
10. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
11. Spherix Reports Second Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... RIDGEFIELD, Conn. , May 17, 2013 /PRNewswire/ ... discussion in respiratory disease at the American Thoracic ... Philadelphia, PA , May 17 – 22. ... a product approved for the treatment of chronic ... inhalation powder)], as well as investigational compounds for ...
(Date:5/17/2013)... 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... JAKARTA , examining the selective JAK2 inhibitor ... both dose groups. The primary endpoint assessed the proportion ... with data reported in previous trials, the most common ... results will be presented at an upcoming medical congress. ...
(Date:5/17/2013)... May 17, 2013  Boston Scientific Corporation (NYSE: ... annual EuroPCR Scientific Program May 21-24 in ... present a particularly rich and diversified set of data ... , M.D., global chief medical officer, Boston Scientific.  ... presented, including the NG PROMUS trial, which evaluated our ...
Breaking Medicine Technology:Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8
... Feb. 8, 2011 IPC The Hospitalist Company, Inc. (Nasdaq: ... practice company, announced today that it will report results for ... Monday, March 7, 2011, after the market close. ... 5:00 p.m. ET (2:00 p.m. PT) on March 7, 2011 ...
... and IRVINE, Calif., Feb. 8, 2011 ... MASI ) jointly announced today a ... Masimo rainbow® SET Pulse CO-Oximetry™ technology platform a ... product line-up—providing clinicians with a host of innovative ...
Cached Medicine Technology:IPC The Hospitalist Company, Inc. to Report Fourth Quarter 2010 Results 2Welch Allyn Establishes Strategic Partnership to Incorporate Masimo rainbow® SET Noninvasive Measurement Capabilities in Next-Generation Patient Monitors 2Welch Allyn Establishes Strategic Partnership to Incorporate Masimo rainbow® SET Noninvasive Measurement Capabilities in Next-Generation Patient Monitors 3Welch Allyn Establishes Strategic Partnership to Incorporate Masimo rainbow® SET Noninvasive Measurement Capabilities in Next-Generation Patient Monitors 4Welch Allyn Establishes Strategic Partnership to Incorporate Masimo rainbow® SET Noninvasive Measurement Capabilities in Next-Generation Patient Monitors 5Welch Allyn Establishes Strategic Partnership to Incorporate Masimo rainbow® SET Noninvasive Measurement Capabilities in Next-Generation Patient Monitors 6
(Date:5/19/2013)... New York (PRWEB) May 19, 2013 ... in a federal litigation now underway in U.S. District ... Case Management Order dated May 3rd, the Court has ... Nominee Pool to eight cases rather than four. The ... scheduled for Thursday, May 23rd. (In re: Actos Product ...
(Date:5/19/2013)... Grinding your teeth at night can ... annoying your spouse. At the same time, according to ... and Teeth Grinding Could Be a Sign of Sleep ... be hard to prevent. Apparently, Obstructive Sleep Disorder (OSD) ... its symptoms is a habit of teeth grinding along ...
(Date:5/19/2013)... 19, 2013 These molecular diagnostics ... UK, Spain, Japan, Italy, Germany and France:, ... diagnostics laboratory practice, as well as key economic, ... market impact during the next five years. , ... biochip technologies, test formats, detection methodologies, trends in ...
(Date:5/19/2013)... May 19, 2013 The Pradaxa lawyers ... Conference was recently convened for hundreds of Pradaxa ... now underway in U.S. District Court, Southern District of ... website on May 14th, the Conference addressed the status ... reported during the Conference that Defendants submitted a list ...
(Date:5/19/2013)... Chertok now provides gum disease patients with a new alternative ... of a healthier smile. Laser gum surgery or ... diseased gum tissue in patients, but it also stimulates bone ... , LANAP uses a laser to successfully treat and ... healthy tissue as well as encourage new bone growth. With ...
Breaking Medicine News(10 mins):Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 2Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 2Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 3Health News:Berkeley, CA Periodontist, Dr. Keith Chertok Now Treats Gum Disease Patients With Laser Gum Surgery Prior to Placing Dental Implants 2
... ... disseminating information on dentistry,s role in the recognition and management of snoring and sleep apnea, ... second month in a row. , ... New York, NY (PRWEB) July 31, 2009 -- Snoring Isn,t Sexy, LLC, a company ...
... WASHINGTON, July 30 Speaker Nancy Pelosi released the following statement ... will give the Food and Drug Administration (FDA) new enforcement tools ... The House passed the bill this evening by a vote of ... deserve to have confidence that the food they are feeding their ...
... , Calls on Senate to Follow ... president and CEO Pamela G. Bailey today commended the members of the ... Enhancement Act of 2009. The bill passed the House by a ... Food Safety Enhancement Act of 2009 marks an important milestone," said Ms. ...
... papillomavirus infection linked to better prognosis, research suggests , ... human papillomavirus (HPV) may improve survival in patients with ... said the finding may explain why black Americans, who ... head and neck cancer survival rates. , "There is ...
... , , WASHINGTON, July ... Representatives Subcommittee on Research and Science Education, part of the larger ... testified on its contributions as a private sector company in a ... technology, engineering and mathematics (STEM) education. , , ...
... DETROIT, July 30 The following is a statement ... , Congressman Thaddeus McCotter is misguided in his attempts ... the Cambridge Police Department. If Congressman McCotter is interested in ... apology to the citizens of Michigan for the current state of ...
Cached Medicine News:Health News:SnoringIsntSexy.com Tops 21,000 Site Visits for Second Month in a Row 2Health News:GMA Applauds U.S. House for Passage of Landmark Food Safety Bill 2Health News:Virus May Affect Survival in Head and Neck Cancer 2Health News:Abbott Testifies Before U.S. Congress on Role of Private Sector in Advancing Science Education 2Health News:Abbott Testifies Before U.S. Congress on Role of Private Sector in Advancing Science Education 3
... Used retrograde to ... establish a Peel-Away ureteral ... The temporary protective Peel-Away ... away as the ureteroscope ...
The removable inflation/injection adapter allows the cystoscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
Radiopaque markers are placed at the proximal and distal ends of the balloon. A special pin vise handle is included to stabilize the wire guide during introduction. Supplied sterile in peel-open pack...
Used during the performance of balloon dilation procedures to inflate and deflate the balloon and measure the pressure within the balloon during the procedure. Supplied sterile in peel-open packages....
Medicine Products: